PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PD PagerDuty, Inc.

交易中 07-24 13:19:36 EDT

20.66

-0.18

-0.86%

最高21.23	最低20.59	成交量35.81万
今开20.76	昨收20.84	日振幅3.07%
总市值19.75亿	流通市值18.88亿	总股本9,560万
成交额750.33万	换手率0.39%	流通股本9,140万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"PD","market":"US","secType":"STK","nameCN":"PagerDuty, Inc.","latestPrice":20.66,"timestamp":1721841568320,"preClose":20.84,"halted":0,"volume":358091,"delay":0,"floatShares":91399714,"shares":95600016,"eps":-1.009878,"marketStatus":"交易中","marketStatusCode":2,"change":-0.18,"latestTime":"07-24 13:19:36 EDT","open":20.76,"high":21.23,"low":20.59,"amount":7503256.187589999,"amplitude":0.03071,"askPrice":20.68,"askSize":10,"bidPrice":20.65,"bidSize":152,"shortable":3,"etf":0,"ttmEps":-1.009878,"exchange":"NYSE","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1721851200000},"adr":0,"listingDate":1554955200000,"adjPreClose":20.84,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":20.71,"preClose":20.84,"latestTime":"08:47 EDT","volume":6,"amount":124.64999999999999,"timestamp":1721825227350},"postHourTrading":{"tag":"盘后","latestPrice":20.86,"preClose":20.84,"latestTime":"17:37 EDT","volume":33368,"amount":695405.92,"timestamp":1721770646375},"volumeRatio":0.418679,"impliedVol":0.4488,"impliedVolPercentile":0.4048},"requestUrl":"/m/hq/s/PD","defaultTab":"news","newsList":[{"id":"2452458483","title":"Pagerduty, Inc.盘中异动 快速下挫5.10%报20.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452458483","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452458483?lang=zh_cn&edition=full","pubTime":"2024-07-19 02:11","pubTimestamp":1721326261,"startTime":"0","endTime":"0","summary":"北京时间2024年07月19日02时11分，Pagerduty, Inc.股票出现异动，股价急速下挫5.10%。Pagerduty, Inc.股票所在的软件服务行业中，整体跌幅为1.26%。Pagerduty, Inc.公司简介：PagerDuty 是一个数字运营管理平台，可为现代数字业务管理紧急和任务关键型工作。该公司的产品包括PagerDuty事故管理、DevOps、AIOPs、流程自动化和客户服务运营。该信息摘要如下：PagerDuty获 高盛 首次覆盖，给予中性评级，目标价24.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407190211029681e224&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407190211029681e224&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1169590202.USD","BK4023","PD","LU1169589451.USD"],"gpt_icon":0},{"id":"2452488068","title":"PagerDuty(PD.US)获高盛首次覆盖，给予中性评级，目标价24.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452488068","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452488068?lang=zh_cn&edition=full","pubTime":"2024-07-18 19:54","pubTimestamp":1721303697,"startTime":"0","endTime":"0","summary":"PagerDuty(PD.US)获 高盛 首次覆盖，给予中性评级，目标价24.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071820072195d5c90b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071820072195d5c90b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PD"],"gpt_icon":0},{"id":"2452116288","title":"Pagerduty, Inc.盘中异动 股价大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452116288","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452116288?lang=zh_cn&edition=full","pubTime":"2024-07-18 00:20","pubTimestamp":1721233200,"startTime":"0","endTime":"0","summary":"北京时间2024年07月18日00时20分，Pagerduty, Inc.股票出现波动，股价大幅上涨5.01%。Pagerduty, Inc.股票所在的软件服务行业中，整体跌幅为1.91%。Pagerduty, Inc.公司简介：PagerDuty 是一个数字运营管理平台，可为现代数字业务管理紧急和任务关键型工作。该公司的产品包括PagerDuty事故管理、DevOps、AIOPs、流程自动化和客户服务运营。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407180020009681db78&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407180020009681db78&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4023","PD","LU1169590202.USD","LU1169589451.USD"],"gpt_icon":0},{"id":"2452181876","title":"亚马逊推出新功能，打响PD大促第一枪","url":"https://stock-news.laohu8.com/highlight/detail?id=2452181876","media":"白鲸出海","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2452181876?lang=zh_cn&edition=full","pubTime":"2024-07-17 15:40","pubTimestamp":1721202000,"startTime":"0","endTime":"0","summary":"图源：亚马逊7 月 16 日至 17 日，第十届亚马逊 Prime 会员日将在全球举行。在大促开始前，亚马逊宣布推出了一个新功能，助推大促。当被问及关键的选举议题时，Rufus 会引导用户查看亚马逊搜索结果，展示此话题的相关信息。事实上，在今年 2 月份，亚马逊就小范围的推出并测试了 AI 购物助手 Rufus。据悉，亚马逊从美国站关键词搜索结果里抽取了 10% 来测试新的 AI 排名机制，进行了为期几个月的 A/B 测试。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071715411695cd4480&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071715411695cd4480&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1169589451.USD","BK4023","LU0097036916.USD","LU0048584097.USD","LU0107464264.USD","AMZN","BK4507","IE00B4JS1V06.HKD","BK4579","IE00BKDWB100.SGD","IE0004086264.USD","LU0096362180.USD","BK4548","IE00BJTD4V19.USD","ADBE","IE00B19Z9505.USD","LU0061474705.USD","PD","BK4581","LU0096364046.USD","LU0082616367.USD","BK4533","BK4534","IE0034235303.USD","IE0005OL40V9.USD","GB00BDT5M118.USD","IE00B775H168.HKD","IE00B7KXQ091.USD","BK4585","IE00B19Z8W00.USD","IE00B775SV38.USD","BK4561","IE00BFSS8Q28.SGD","IE00BK4W5M84.HKD","BK4538","LU0061474960.USD","IE00BMPRXQ63.HKD","IE00BJLML261.HKD","IE00BFSS7M15.SGD","IE00BKPKM429.USD","IE00BJJMRY28.SGD","BK4535","BK4503","BK4559","IE00B19Z8X17.USD","IE0004445239.USD","IE00BWXC8680.SGD","BK4554","BK4220","IE00B1XK9C88.USD","IE0004091025.USD"],"gpt_icon":1},{"id":"2452188325","title":"百时美施贵宝(BMY.US)PD-1 单抗新适应症在中国申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2452188325","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452188325?lang=zh_cn&edition=full","pubTime":"2024-07-17 14:24","pubTimestamp":1721197454,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月17日，CDE官网显示，百时美施贵宝已在中国递交了纳武利尤单抗注射液的又一新适应症上市申请，并获得受理。纳武利尤单抗是一款PD-1抑制剂，此前已在中国获批9项适应症。根据公开资料推测该药本次申报上市的新适应症可能为肝细胞癌。自上市以来，纳武利尤单抗的销售额也是一路上涨，2022年全球销售额已达82.49亿美元，2023年仍保持上涨趋势，达到90.09亿美元，仍是百时美施贵宝营收的主要来源之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1151957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169589451.USD","LU0114720955.EUR","LU1670710588.SGD","LU0456855351.SGD","BK4534","BK4559","LU0882574055.USD","LU0321505439.SGD","IE00BJT1NW94.SGD","LU1430594728.SGD","LU1670711040.USD","LU2125154778.USD","IE00BJJMRZ35.SGD","BK4585","LU2242652126.USD","LU2360032135.SGD","LU2125154935.USD","LU1032466523.USD","LU2242646821.SGD","IE0009355771.USD","LU2133065610.SGD","LU1585245621.USD","LU1670710661.SGD","BK4532","LU0868494617.USD","IE00BFTCPJ56.SGD","LU1074936037.SGD","LU1718418525.SGD","PD","LU0061475181.USD","BK4581","LU1169590202.USD","LU1670711123.USD","LU1989771016.USD","BK4007","BMY","BK4023","IE00B2B36J28.USD","LU0237698245.USD","IE0002141913.USD","IE00BSNM7G36.USD","LU1261432733.SGD","LU0321505868.SGD","LU1571399168.USD","LU1291159041.SGD","BK4588"],"gpt_icon":0},{"id":"2450854258","title":"后PD-1时代重磅品种IND获受理 加科思(01167)驶向快车道","url":"https://stock-news.laohu8.com/highlight/detail?id=2450854258","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450854258?lang=zh_cn&edition=full","pubTime":"2024-07-10 08:49","pubTimestamp":1720572585,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月10日，国家药品监督管理局药品审评中心网站显示加科思的泛KRAS抑制剂JAB-23E73的新药临床试验申请已获受理，该产品是目前全球进度第一的口服广谱KRAS抑制剂。在核心管线方面，加科思已经在5月递交了KRAS G12C抑制剂glecirasib的二线非小细胞肺癌适应症新药上市申请，即将为公司首次带来商业化收入。加科思还拥有全球唯一进入注册性临床阶段的SHP2抑制剂JAB-3312，计划通过联合用药成为全球一线疗法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1148341.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169589451.USD","PD","BK4023","BK1161","01167","BK1574","LU1169590202.USD"],"gpt_icon":0},{"id":"2450095094","title":"临床失利 康宁杰瑞PD-L1出海遇阻","url":"https://stock-news.laohu8.com/highlight/detail?id=2450095094","media":"中国经营报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450095094?lang=zh_cn&edition=full","pubTime":"2024-07-09 15:26","pubTimestamp":1720509980,"startTime":"0","endTime":"0","summary":"本报记者 张悦 曹学平 北京报道近日，康宁杰瑞生物制药（09966.HK）的美国合作伙伴TRACON Pharmaceuticals, Inc.（以下简称“TRACON”) 宣布，由于临床关键试验未达到主要终点，将终止对恩沃利单抗的进一步开发。恩沃利单抗（研发代号：KN035）是康宁杰瑞目前唯一的商业化产品，2021年获国家药监局附条件上市批准。上市之时...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240709A05C3W00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240709A05C3W00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["LU1169590202.USD","BK4588","LU0348723411.USD","PD","BK4512","GLW","LU1169589451.USD","BK4148","BK4585","BK4023"],"gpt_icon":0},{"id":"2448641864","title":"Checkpoint Therapeutics(CKPT.US)向美国FDA提交其PD-L1靶向抗体上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2448641864","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448641864?lang=zh_cn&edition=full","pubTime":"2024-07-04 10:37","pubTimestamp":1720060652,"startTime":"0","endTime":"0","summary":"日前，Checkpoint Therapeutics(CKPT.US)宣布已向美国FDA重新提交其PD-L1靶向抗体cosibelimab的生物制品许可申请(BLA)。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20240704/20240704103720_42181.png?x-oss-process=image/format,jpg/quality,Q_80","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240704/20240704103720_42181.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1145432.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1169589451.USD","LENZ","CKPT","PD","BK4023","LU1169590202.USD","BK4139"],"gpt_icon":0},{"id":"2448157409","title":"康宁杰瑞PD-L1海外临床失败，翻盘概率渺茫","url":"https://stock-news.laohu8.com/highlight/detail?id=2448157409","media":"健识局","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448157409?lang=zh_cn&edition=full","pubTime":"2024-07-02 22:06","pubTimestamp":1719929205,"startTime":"0","endTime":"0","summary":"就在5月29日，康宁杰瑞另一核心产品KN046针对晚期胰腺导管癌临床试验失败。PD-L1美国临床失败康宁杰瑞出海遇阻7月1日，美国制药公司TRACON宣布，将终止恩沃利单抗的进一步开发。恩沃利单抗注是康宁杰瑞自主研发的PD-L1单抗，相比于其他竞品的最大亮点在于剂型为皮下注射。就在不久前，康宁杰瑞的核心产品PD-L1/CTLA-4双抗KN046刚刚遭遇了一场重大失利。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407022210319566f7b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407022210319566f7b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1169589451.USD","BK4148","PD","BK4023","BK4585","BK4512","LU1169590202.USD","LU0348723411.USD","BK4588","GLW"],"gpt_icon":0},{"id":"2446524941","title":"美国研究综述-Equity Residential、高盛、Marsh & Mclennan","url":"https://stock-news.laohu8.com/highlight/detail?id=2446524941","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446524941?lang=zh_cn&edition=full","pubTime":"2024-06-28 15:42","pubTimestamp":1719560556,"startTime":"0","endTime":"0","summary":"    路透6月28日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，其中包括 Equity Residential、高盛和 Marsh & Mclennan。要点 * Equity Residential   ：Piper Sandler 将其评级从 \"中性 \"上调至 \"增持\"。* 高盛   ：加拿大皇家银行将目标价从 405 美元上调至 435 美元  * Marsh & Mclennan   ：加拿大皇家银行将目标价从210美元上调至228美元  * Pagerduty Inc   ：丰业银行给予其行业表现评级 * Williams Companies Inc   ：摩根大通将目标价从42美元上调至47美元  以下是路透周五报导的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0820562030.AUD","GE","LU0689472784.USD","RXRX","APOG","BK4092","LU0640476718.USD","MMC","HAL","IE00B19Z3581.USD","LBRT","LU0820561909.HKD","BKR","WMB","ACCD","EQR","LU1162221912.USD","PD","BK4139","DAL","BK4558","BK4550","BK4501","LU0149725797.USD","NKE","BK4146","LU0310800965.SGD","HP","LU2023250504.SGD","LU1064131342.USD","NINE","BK4559","PTEN","BK4552","GS","BP","LU0170899867.USD","PUMP","MKC","LU1983260115.SGD","SM","LU1668664300.SGD","LU1917777945.USD","VKTX","WBA","LU1303367103.USD","GIS","LU1169590202.USD","CALC","LU1430594728.SGD"],"gpt_icon":0},{"id":"2446523935","title":"“木头姐”为何大手笔押注这三只暴跌股？揭秘它们的魅力与潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2446523935","media":"FX168","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446523935?lang=zh_cn&edition=full","pubTime":"2024-06-27 23:28","pubTimestamp":1719502113,"startTime":"0","endTime":"0","summary":"FX168财经报社 讯 对于凯西·伍德的投资风格来说，这是一个充满挑战的时期。Ark Invest的联合创始人、首席执行官兼投资者发现，伍德的激进增长型交易所交易基金家族在2024年四年内第三次输给市场。她能重回正轨吗？她当然不会停滞不前。#2024宏观展望# #2024投资策略#. Ark Invest周二采取了多项举措，Roku、Blade Air Mobility和Pager Duty霍然显示在其购物清单上。Ark Invest现在持有Roku总流通股的9%以上。本月，对Pager Duty青睐有加的不仅仅是Wood。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fx168news.com/article/美国股市-742493","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4507","BK4524","BK4023","LU1861558580.USD","LU1169589451.USD","BK4108","BLDE","BK4532","BK4585","LU1861559042.SGD","ROKU","BK4008","BK4564","PD","BK4588","LU1169590202.USD"],"gpt_icon":0},{"id":"2446555512","title":"PagerDuty(PD.US)获小摩首次覆盖，给予中性评级, 目标价24.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446555512","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446555512?lang=zh_cn&edition=full","pubTime":"2024-06-27 21:36","pubTimestamp":1719495408,"startTime":"0","endTime":"0","summary":"PagerDuty(PD.US)获小摩首次覆盖，给予中性评级,目标价24.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062721472695de7f07&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062721472695de7f07&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PD"],"gpt_icon":0},{"id":"2443697766","title":"信达生物在2024年欧洲肿瘤内科学会（ESMO）六月全体大会口头报告全球首创PD-1/IL-2α-bias双特异性抗体融合蛋白IBI363治疗晚期非小细胞肺癌等实体瘤的临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2443697766","media":"美通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443697766?lang=zh_cn&edition=full","pubTime":"2024-06-14 08:48","pubTimestamp":1718326080,"startTime":"0","endTime":"0","summary":"\" PD-1/IL-2α-bias双特异性抗体融合蛋白治疗晚期实体瘤的的I期临床数据 本项研究为Ia/Ib期研究，旨在评估IBI363治疗晚期实体瘤受试者的安全性、耐受性和初步有效性。IBI363作为PD-1/IL-2α-bias双特异性分子，初步研究结果提示在免疫耐药的黑色素瘤具有显著优于目前标准治疗的客观缓解率，并且缓解持久。IBI363治疗在黑色素瘤人群中耐受性良好，整体安全性风险可控。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4439708_ZH39708_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1169589451.USD","LU2328871848.SGD","PD","BK4139","01801","BK1583","BK1161","BK4023","IVBIY","LU1969619763.USD","BK1589","LU1169590202.USD"],"gpt_icon":0},{"id":"2442149554","title":"Pagerduty, Inc.盘中异动 早盘股价大涨6.12%报21.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2442149554","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442149554?lang=zh_cn&edition=full","pubTime":"2024-06-12 21:30","pubTimestamp":1718199024,"startTime":"0","endTime":"0","summary":"北京时间2024年06月12日21时30分，Pagerduty, Inc.股票出现波动，股价快速上涨6.12%。截至发稿，该股报21.50美元/股，成交量8.1131万股，换手率0.08%，振幅0.00%。Pagerduty, Inc.股票所在的软件服务行业中，整体涨幅为0.55%。Pagerduty, Inc.公司简介：PagerDuty 是一个数字运营管理平台，可为现代数字业务管理紧急和任务关键型工作。该公司的产品包括PagerDuty事故管理、DevOps、AIOPs、流程自动化和客户服务运营。消息层面，截至21时30分，《Craig-Hallum首予PagerDuty买入评级，目标价30美元》资讯为影响Pagerduty, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240612213024941ee079&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240612213024941ee079&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PD","CYN","LU1169590202.USD","LU1169589451.USD","BK4023"],"gpt_icon":0},{"id":"2441032415","title":"恒瑞澄清FDA483表格：出口美国制剂暂未受影响，与PD-1组合申报无关","url":"https://stock-news.laohu8.com/highlight/detail?id=2441032415","media":"蓝鲸财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441032415?lang=zh_cn&edition=full","pubTime":"2024-06-07 16:53","pubTimestamp":1717750411,"startTime":"0","endTime":"0","summary":"近日，有媒体报道称，恒瑞医药收到美FDA发出的483表格。蓝鲸财经在FDA官网查询该报告显示，恒瑞医药收到的FDA 483表的出示时间为今年1月16日，而FDA目前已经对其出具了OAI。目前公司出口美国的制剂未受到影响。对于部分投资者十分关注的、此次483与恒瑞PD-1组合疗法在美国申报上市是否有关系这一问题，恒瑞医药表示，根据FDA法规，对药品生产场地按照注册地址分别管理。本次检查结果与公司PD-1组合疗法在美国申报上市没有关联。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/233255","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU1169590202.USD","PD","BK4023","LU1169589451.USD"],"gpt_icon":0},{"id":"2441223446","title":"中生制药(01177.HK)发布FS222“CD137/PD-L1”一期阳性临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2441223446","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441223446?lang=zh_cn&edition=full","pubTime":"2024-06-05 17:58","pubTimestamp":1717581480,"startTime":"0","endTime":"0","summary":"中生制药(01177.HK) 公布，附属invoX Pharma已在2024年美国临床肿瘤学会(ASCO)年会上，以口头报告形式公布了FS222“CD137/PD-L1”正在进行的一期临床试验的最新成果，用于治疗晚期实体瘤患者。数据显示，该产品在多种肿瘤类型中展现出强大的抗肿瘤活性，且安全性可控。公司表示，FS222的一期临床试验正在招募受试者，研究将进一步探索FS222的剂量优化，未来会加速FS222的临床开发，并继续利用旗下专有抗体平台开发更多的药物。(gc/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-06-05 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190401142440189_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190401142440189_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1354651/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1589","BK1521","01177","BK4023","LU1169589451.USD","PD","LU1169590202.USD","01477","BK1574","BK1515","BK1191"],"gpt_icon":0},{"id":"2441223122","title":"中国生物制药(01177)：FS222“CD137/PD-L1”I期阳性临床数据展现出强大的抗肿瘤活性，且安全性可控","url":"https://stock-news.laohu8.com/highlight/detail?id=2441223122","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441223122?lang=zh_cn&edition=full","pubTime":"2024-06-05 17:56","pubTimestamp":1717581374,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 公布，公司全资附属公司invoX Pharma Limited已在2024年美国临床肿瘤学会年会上以口头报告的形式公布了FS222“CD137/PD-L1”正在进行的I期临床试验的最新成果，用于晚期实体瘤患者。总体而言，TRAE与预期的CD137激动和PD-L1阻断双重作用机制一致，并且通常是可控和可逆的。在研究中，FS222在多种肿瘤类型中展现出了强大的抗肿瘤活性。FS222的I期临床试验正在招募受试者，该研究正在进一步探索FS222的剂量优化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1131467.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PD","BK1521","BK1515","BK4023","LU1169589451.USD","LU1169590202.USD","BK1589","01177","BK1191"],"gpt_icon":0},{"id":"2440546120","title":"康方生物(09926)修订与Summit关于依沃西(PD-1/VEGF)的许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2440546120","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440546120?lang=zh_cn&edition=full","pubTime":"2024-06-03 19:36","pubTimestamp":1717414590,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康方生物 发布公告，于2024年6月3日，公司与Summit订立许可协议的修订，公司与Summit同意扩大许可协议项下的许可地区。根据许可协议修订，公司可获得7000万美元的首付款和里程碑款，以及经扩大Summit许可地区的销售提成。公司将继续为包括经扩大Summit许可地区在内的许可地区供应依沃西，并获得供货收入。Summit将新增获得在中美洲、南美洲、中东地区和非洲相关市场开发依沃西的独家权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1130298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1720050803.USD","09926","LU0348784397.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU0348783233.USD","LU1169589451.USD","PD","LU1794554557.SGD","BK4023","BK1161","BK1574","LU0417516571.SGD","LU1169590202.USD"],"gpt_icon":0},{"id":"2440618354","title":"重磅！国产PD-L1单抗有望亮剑欧洲！基石药业涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2440618354","media":"财华社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440618354?lang=zh_cn&edition=full","pubTime":"2024-06-03 19:18","pubTimestamp":1717413517,"startTime":"0","endTime":"0","summary":"6月3日，基石药业-B（02616.HK）股价在高开后呈现显著上涨态势，盘中一度实现涨幅高达18.97%。尽管随后股价有所回落，但截至收盘时，其涨幅仍保持在10.34%的较高水平。在当日生物科技市场表现中，基石药业-B的涨幅仅次于加科思-B（01167.HK）的11.54%，展现出强劲的股价走势。","market":"us","thumbnail":"https://images.finet.hk/photoLib/title/202406_1/1c9e3ba5-b7d6-4774-854f-6b7be81f93f7.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202406_1/1c9e3ba5-b7d6-4774-854f-6b7be81f93f7.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/665da68d53243c0dd2af9f8f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["LU1169589451.USD","BK4023","LU1169590202.USD","PD"],"gpt_icon":0},{"id":"2440934431","title":"信达生物在2024年美国临床肿瘤学会（ASCO）年会公布全球首创PD-1/IL-2α双特异性抗体融合蛋白（IBI363）治疗晚期黑色素瘤、结直肠癌等肿瘤的I期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2440934431","media":"美通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440934431?lang=zh_cn&edition=full","pubTime":"2024-06-02 08:00","pubTimestamp":1717286400,"startTime":"0","endTime":"0","summary":"PD-1/IL-2α双特异性抗体融合蛋白治疗晚期黑色素瘤、结直肠癌等肿瘤的I期临床数据 本项研究为Ia/Ib期研究，旨在评估IBI363治疗晚期实体瘤受试者的安全性、耐受性和初步有效性。在4例确认的PR受试者中，3例仍在接受IBI363治疗，1例头颈鳞癌患者接受了根治性切除手术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4428966_ZH28966_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1169589451.USD","IVBIY","BK1589","LU1969619763.USD","BK1161","PD","01801","LU2328871848.SGD","BK4023","LU1169590202.USD","BK1583","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pagerduty.com","stockEarnings":[{"period":"1week","weight":0.0039},{"period":"1month","weight":-0.0262},{"period":"3month","weight":0.0039},{"period":"6month","weight":-0.1291},{"period":"1year","weight":-0.1262},{"period":"ytd","weight":-0.0998}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.017},{"period":"3month","weight":0.0957},{"period":"6month","weight":0.1347},{"period":"1year","weight":0.2192},{"period":"ytd","weight":0.1651}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"PagerDuty, Inc.于2010年5月根据特拉华州法律注册成立。PagerDuty是数字企业的中枢神经系统。PagerDuty利用几乎任何支持软件的系统或设备的数字信号，将其与人工响应数据相结合，并协调团队实时采取正确的行动。公司的产品可帮助组织改善运营，加速创新，增加收入，降低安全风险并提供出色的客户体验。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.052063},{"month":2,"riseRate":0.6,"avgChangeRate":-0.030334},{"month":3,"riseRate":0.4,"avgChangeRate":-0.028164},{"month":4,"riseRate":0.4,"avgChangeRate":-0.029577},{"month":5,"riseRate":0.333333,"avgChangeRate":0.0049},{"month":6,"riseRate":0.666667,"avgChangeRate":0.013501},{"month":7,"riseRate":0.5,"avgChangeRate":0.010994},{"month":8,"riseRate":0.6,"avgChangeRate":0.002566},{"month":9,"riseRate":0,"avgChangeRate":-0.144809},{"month":10,"riseRate":0.4,"avgChangeRate":-0.040139},{"month":11,"riseRate":0.6,"avgChangeRate":0.044973},{"month":12,"riseRate":0.6,"avgChangeRate":0.069164}],"exchange":"NYSE","name":"PagerDuty, Inc.","nameEN":"PagerDuty, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供PagerDuty, Inc.(PD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"PagerDuty, Inc.,PD,PagerDuty, Inc.股票,PagerDuty, Inc.股票老虎,PagerDuty, Inc.股票老虎国际,PagerDuty, Inc.行情,PagerDuty, Inc.股票行情,PagerDuty, Inc.股价,PagerDuty, Inc.股市,PagerDuty, Inc.股票价格,PagerDuty, Inc.股票交易,PagerDuty, Inc.股票购买,PagerDuty, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供PagerDuty, Inc.(PD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}